SYMBIOTEC · Symbiotec Pharmalab Limited
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since Sep 1, 2026; less than a full year is stored.
Latest documents
Symbiotec Pharmalab Limited reported Q1 FY27 revenue of INR218 crores, up 7% year-on-year, EBITDA of INR45 crores and net profit of about INR14 crores. FY27 targets 20% revenue and 25% EBITDA growth; new-business revenues expected in 6 to 12 months.
Quarterly results
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:SYMBIOTEC | +6.6% | +28.5% | — | +29.6% | — |
Exchange listing
- Market
- XBOM
- Ticker
- SYMBIOTEC
- ISIN
- INE899I01028
- Security
- Ordinary share
- Trading currency
- INR
Company
- Website
- https://www.symbiotec.com/
- Investor relations
- https://investor.symbiotec.com/
Other listings of this company
Share classes and depositary receipts can have different prices and dividends.
Recent dividends
No verified dividend payments are available for this listing yet.
Upcoming investor events
No upcoming investor events are listed for this company yet.
Earnings calls
-
Earnings call · Q2 2027 2026-11-06 TranscriptEarnings Call for the Quarter Ended September 30, 2026
-
Earnings call · Q1 2027 2026-09-22 TranscriptEarnings Call